drugset
Drugs / MEDI-517
last change Jan 2005 re-read 3 minutes ago

MEDI-517

also known as GSK 580299 · MEDI-517 HPV-16/18 VLP AS04 vaccine · MEDI-517 HPV-16/18 VLP vaccine with Al(OH)3

Vaccine

Developed for
human papilloma virus infection
Investigated by
GlaxoSmithKline · MedImmune LLC

Trials 3

today NCT00693615 · Ph 2 NCT00263744 · Ph 1/2 NCT00693966 · Ph 2
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT00263744 Nov 1999 → Apr 2001 — MedImmune LLC Completed No outcome recorded
Phase 22 trials
Phase 2 NCT00693615 Oct 2000 → Jan 2005 human papilloma virus infection GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00693966 Oct 1999 → Sep 2004 human papilloma virus infection GlaxoSmithKline Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as MEDI-517 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00693615 ↗
2

NCT00693966 ↗

NCT00263744 ↗
Known as GSK 580299 “MEDI-517 (GSK 580299)” NCT00693966 ↗
Known as MEDI-517 HPV-16/18 VLP AS04 vaccine “MEDI-517 HPV-16/18 VLP AS04 vaccine” NCT00693615 ↗
Known as MEDI-517 HPV-16/18 VLP vaccine with Al(OH)3 “MEDI-517 HPV-16/18 VLP vaccine with Al(OH)3” NCT00693615 ↗
Modality Vaccine “Virus-Like Particle Vaccine” NCT00693615 ↗
Route Intramuscular “given at 0, 30, and 180 days by intramuscular injection” NCT00693615 ↗